Company / R&D Expense
Cytek Biosciences, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$36.5M
FY2025
5-year range
$13.7M / $44.2M
FY2021-FY2025
Trend
-7.4%
vs FY2024
Sector context
#90 of 110
Health Care
What the data says
Cytek Biosciences, Inc.'s r&d expense of $36M is lower than 82% of companies in the Health Care sector (FY2025). Declined from $44M to $36M over the past 2 years.
Based on SEC 10-K filings.
$36M in FY2025 with a 5-year CAGR of +21.6%.
Declined from $44M to $36M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +1.5%
- 5-Year CAGR
- +21.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 110This company $36.5M Sector average $298.2M
▼
-87.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.6%, indicating consistent growth.
- In FY2025, r&d expense decreased 7.4% year-over-year.
- Ranks #90 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $36.5M | -7.4% |
| FY2024 | $39.4M | -10.8% |
| FY2023 | $44.2M | +26.7% |
| FY2022 | $34.9M | +154.6% |
| FY2021 | $13.7M | +0.0% |
| FY2020 | $13.7M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026